Biomarkers, Tumor

"Biomarkers, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS.

Descriptor ID	D014408
MeSH Number(s)	D23.101.140
Concept/Terms	Biomarkers, Tumor Biomarkers, Tumor Tumor Biomarkers Markers, Biological Tumor Tumor Markers, Biological Markers, Tumor Metabolite Tumor Metabolite Markers Metabolite Markers, Tumor Marker, Tumor Metabolite Metabolite Marker, Tumor Tumor Metabolite Marker Tumor Markers, Biologic Biologic Tumor Markers Markers, Biologic Tumor Marker, Biologic Tumor Biologic Tumor Marker Tumor Marker, Biologic Biochemical Tumor Markers Markers, Biochemical Tumor Marker, Biochemical Tumor Biochemical Tumor Marker Tumor Marker, Biochemical Tumor Markers, Biochemical Carcinogen Markers Markers, Carcinogen Markers, Neoplasm Metabolite Neoplasm Metabolite Markers Marker, Neoplasm Metabolite Metabolite Marker, Neoplasm Neoplasm Metabolite Marker Metabolite Markers, Neoplasm Biological Tumor Markers Biological Tumor Marker Tumor Marker, Biological Marker, Biological Tumor Markers, Tumor Markers, Tumor Tumor Markers Biomarkers, Cancer Cancer Biomarkers

Below are MeSH descriptors whose meaning is more general than "Biomarkers, Tumor".

Chemicals and Drugs [D]
Biological Factors [D23]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]

Below are MeSH descriptors whose meaning is related to "Biomarkers, Tumor".

Below are MeSH descriptors whose meaning is more specific than "Biomarkers, Tumor".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Biomarkers, Tumor" by people in this website by year, and whether "Biomarkers, Tumor" was a major or minor topic of these publications.

Bar chart showing 4321 publications over 30 distinct years, with a maximum of 303 publications in 2016

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1991	11	6	17
1992	15	11	26
1993	14	12	26
1994	21	14	35
1995	15	11	26
1996	15	20	35
1997	16	15	31
1998	25	27	52
1999	20	27	47
2000	24	35	59
2001	42	33	75
2002	41	47	88
2003	58	64	122
2004	74	56	130
2005	75	85	160
2006	85	79	164
2007	91	72	163
2008	104	72	176
2009	107	88	195
2010	88	125	213
2011	125	129	254
2012	130	126	256
2013	149	105	254
2014	161	101	262
2015	152	107	259
2016	159	144	303
2017	161	139	300
2018	118	145	263
2019	125	123	248
2020	42	40	82

Below are the most recent publications written about "Biomarkers, Tumor" by people in Profiles.

Lin YH, Satani N, Hammoudi N, Yan VC, Barekatain Y, Khadka S, Ackroyd JJ, Georgiou DK, Pham CD, Arthur K, Maxwell D, Peng Z, Leonard PG, Czako B, Pisaneschi F, Mandal P, Sun Y, Zielinski R, Pando SC, Wang X, Tran T, Xu Q, Wu Q, Jiang Y, Kang Z, Asara JM, Priebe W, Bornmann W, Marszalek JR, DePinho RA, Muller FL. An enolase inhibitor for the targeted treatment of ENO1-deleted cancers. Nat Metab. 2020 12; 2(12):1413-1426.

View in: PubMed
Boyukozer FB, Tanoglu EG, Ozen M, Ittmann M, Aslan ES. Kallikrein gene family as biomarkers for recurrent prostate cancer. Croat Med J. 2020 Oct 31; 61(5):450-456.

View in: PubMed
Redman MW, Papadimitrakopoulou VA, Minichiello K, Hirsch FR, Mack PC, Schwartz LH, Vokes E, Ramalingam S, Leighl N, Bradley J, Miao J, Moon J, Highleyman L, Miwa C, LeBlanc ML, Malik S, Miller VA, Sigal EV, Adam S, Wholley D, Sigman C, Smolich B, Blanke CD, Kelly K, Gandara DR, Herbst RS. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. Lancet Oncol. 2020 12; 21(12):1589-1601.

View in: PubMed
Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Lizée G. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun. 2020 10 21; 11(1):5332.

View in: PubMed
Sasaki N, Iwaya T, Chiba T, Fujita M, Ju Z, Endo F, Yaegashi M, Hachiya T, Sugimoto R, Sugai T, Siwak DR, Liotta LA, Lu Y, Mills GB, Nakagawa H, Nishizuka SS. Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. PLoS One. 2020; 15(10):e0239966.

View in: PubMed
Dummer R, Lebbé C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GV. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020 10; 26(10):1557-1563.

View in: PubMed
Jing Y, Liu J, Ye Y, Pan L, Deng H, Wang Y, Yang Y, Diao L, Lin SH, Mills GB, Zhuang G, Xue X, Han L. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020 10 02; 11(1):4946.

View in: PubMed
Abdelhakeem A, Wang X, Rogers JE, Trail A, Zhao M, Blum-Murphy M, Estrella JS, Ajani JA. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. Oncology. 2020; 98(12):884-888.

View in: PubMed
Hou J, Zhao R, Xia W, Chang CW, You Y, Hsu JM, Nie L, Chen Y, Wang YC, Liu C, Wang WJ, Wu Y, Ke B, Hsu JL, Huang K, Ye Z, Yang Y, Xia X, Li Y, Li CW, Shao B, Tainer JA, Hung MC. PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis. Nat Cell Biol. 2020 10; 22(10):1264-1275.

View in: PubMed
Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH, Italiano A, Kao S, Piha-Paul SA, Delord JP, McWilliams RR, Fabrizio DA, Aurora-Garg D, Xu L, Jin F, Norwood K, Bang YJ. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020 10; 21(10):1353-1365.

View in: PubMed

People

Explore

Similar Concepts

Top Journals